iZumi Bio Revenue and Competitors
Estimated Revenue & Valuation
- iZumi Bio's estimated annual revenue is currently $13.9M per year.
- iZumi Bio's estimated revenue per employee is $155,000
Employee Data
- iZumi Bio has 90 Employees.
- iZumi Bio grew their employee count by 18% last year.
iZumi Bio's People
| Name | Title | Email/Phone |
|---|
iZumi Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is iZumi Bio?
iPS cells, cell reprogamming, and cell differentiation for drug discovery
keywords:N/A
N/A
Total Funding
90
Number of Employees
$13.9M
Revenue (est)
18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
iZumi Bio News
2022-04-19 - Balkan, istorija i tehnologija: Slavoljub Penkala - Zagrep?anin ?iji izumi
ive vie od veka
Eduard Penkala je 1902. godine doao do svog prvog pronalaska - bio je to termofor, gumena kesa koja u koju se sipa topla voda i slui za...
2022-04-17 - India needs tough regulations against the foreign biolabs ...
Hunter Biden's bio firm joined hands with Ukrainian researchers to isolate ... Izumi Nakamitsu, the UN Undersecretary stated that all such...
2022-03-22 - Document on Wikileaks 'a proof' US manufactured 'components of bioweapons'
in Kyiv: Russia
UN high commissioner for disarmament, Izumi Nakamitsu said that the ... Igor Kirillov compared US-backed bio-weaponry research with that in...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 90 | 30% | N/A |
#2 | $8.1M | 90 | 6% | N/A |
#3 | $14.9M | 90 | 7% | N/A |
#4 | $24.3M | 90 | 8% | N/A |
#5 | $7.5M | 90 | 8% | N/A |